Impella

Impella is a family of medical devices used as a temporary ventricular support device in people with depressed heart function. Some versions of the device can provide right heart support during other forms of mechanical circulatory support including ECMO and Centrimag. Impella is a family of medical devices used as a temporary ventricular support device in people with depressed heart function. Some versions of the device can provide right heart support during other forms of mechanical circulatory support including ECMO and Centrimag. The device is approved for use in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock following a heart attack or an open heart surgery procedure. It is placed into the heart through a peripheral artery. Once in place, it pumps blood for the left or right side of the heart, pumping blood into the ascending aorta or pulmonary artery, respectively. The Impella technology was acquired by Abiomed in 2005. As of March 2019, the Impella series included the Impella 2.5, Impella 5.0/LD, Impella CP and Impella RP. According to Bloomberg, Abiomed 'engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients'. Earlier in the year, the company had increased its 2019 revenue guidance to approximately $780 million. It results in similar results to veno-arterial extracorporeal life support and TandemHeart.